MX2020002296A - Inhibidor selectivo de egfr mutado en el exon 18 y/o el exon 21. - Google Patents
Inhibidor selectivo de egfr mutado en el exon 18 y/o el exon 21.Info
- Publication number
- MX2020002296A MX2020002296A MX2020002296A MX2020002296A MX2020002296A MX 2020002296 A MX2020002296 A MX 2020002296A MX 2020002296 A MX2020002296 A MX 2020002296A MX 2020002296 A MX2020002296 A MX 2020002296A MX 2020002296 A MX2020002296 A MX 2020002296A
- Authority
- MX
- Mexico
- Prior art keywords
- exon
- selective inhibitor
- mutant egfr
- mutations
- egfr selective
- Prior art date
Links
- 108060006698 EGF receptor Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 230000035772 mutation Effects 0.000 abstract 4
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- MKCYPWYURWOKST-INIZCTEOSA-N NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 MKCYPWYURWOKST-INIZCTEOSA-N 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un agente antitumoral para tratar a un paciente con tumor maligno que expresa EGFR que tiene al menos una mutacion seleccionada del grupo que consiste en la mutacion G719X del exón 18, la mutacion E709X del exon 18 y la mutacion L861X del exon 21, en donde X representa un residuo de aminoacido arbitrario, el agente antitumoral comprende (S)-N-(4-amino-6-metil-5-(quinolin-3-il)-8,9 -dihidropirimido[5,4-b] indolizin-8-il)acrilamida o una sal de la misma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017168606 | 2017-09-01 | ||
| PCT/JP2018/032314 WO2019045036A1 (ja) | 2017-09-01 | 2018-08-31 | エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002296A true MX2020002296A (es) | 2020-09-10 |
Family
ID=65527547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002296A MX2020002296A (es) | 2017-09-01 | 2018-08-31 | Inhibidor selectivo de egfr mutado en el exon 18 y/o el exon 21. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11701359B2 (es) |
| EP (1) | EP3677266B1 (es) |
| JP (1) | JP7065103B2 (es) |
| KR (1) | KR102676530B1 (es) |
| CN (2) | CN117159551A (es) |
| AU (1) | AU2018325819B2 (es) |
| BR (1) | BR112020004000A2 (es) |
| CA (2) | CA3224526A1 (es) |
| DK (1) | DK3677266T5 (es) |
| ES (1) | ES2972895T3 (es) |
| FI (1) | FI3677266T3 (es) |
| HU (1) | HUE066587T2 (es) |
| IL (1) | IL272929B2 (es) |
| JO (1) | JOP20200044A1 (es) |
| MX (1) | MX2020002296A (es) |
| PH (1) | PH12020500419A1 (es) |
| PL (1) | PL3677266T3 (es) |
| PT (1) | PT3677266T (es) |
| SG (1) | SG11202001861WA (es) |
| TW (1) | TWI838345B (es) |
| WO (1) | WO2019045036A1 (es) |
| ZA (1) | ZA202001445B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190073A1 (ar) | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
| DK3677266T5 (da) | 2017-09-01 | 2024-08-26 | Taiho Pharmaceutical Co Ltd | Exon-18- og/eller exon-21-mutant egfr-selektiv hæmmer |
| EP3902548A1 (en) * | 2018-12-28 | 2021-11-03 | Taiho Pharmaceutical Co., Ltd. | L718 and/or l792 mutant treatment-resistant egfr inhibitor |
| US20230372346A1 (en) * | 2020-09-08 | 2023-11-23 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| PE20240327A1 (es) | 2021-04-13 | 2024-02-22 | Nuvalent Inc | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr |
| CN115785107A (zh) * | 2022-12-15 | 2023-03-14 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| BRPI0606281A2 (pt) | 2005-03-17 | 2009-06-09 | Novartis Ag | compostos orgánicos |
| ATE509624T1 (de) | 2005-12-23 | 2011-06-15 | Nutricia Nv | Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz |
| BRPI1013999B1 (pt) | 2009-07-10 | 2020-06-02 | Taiho Pharmaceutical Co., Ltd. | Composto de azabiciclo e um sal deste, produto farmacêutico e composição farmacêutica compreendendo dito composto e uso do mesmo para tratar câncer |
| US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| JP5792201B2 (ja) | 2011-01-07 | 2015-10-07 | 大鵬薬品工業株式会社 | 新規二環式化合物又はその塩 |
| WO2013047813A1 (ja) | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| TW201336847A (zh) | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| CA2861980C (en) | 2012-02-23 | 2016-11-08 | Taiho Pharmaceutical Co., Ltd. | Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof |
| CN105073752B (zh) | 2013-02-22 | 2017-08-15 | 大鹏药品工业株式会社 | 制备三环化合物的方法以及可通过所述制备方法制备的三环化合物 |
| JP6161705B2 (ja) | 2013-08-22 | 2017-07-12 | 大鵬薬品工業株式会社 | 新規キノリン置換化合物 |
| JP6468611B2 (ja) | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| MA40240B1 (fr) | 2014-06-19 | 2019-03-29 | Ariad Pharma Inc | Composés hétéroaryle d'inhibition de la kinase |
| JP6583614B2 (ja) | 2015-05-11 | 2019-10-02 | 大同特殊鋼株式会社 | アーク炉の電極折損防止装置 |
| DK3677266T5 (da) | 2017-09-01 | 2024-08-26 | Taiho Pharmaceutical Co Ltd | Exon-18- og/eller exon-21-mutant egfr-selektiv hæmmer |
-
2018
- 2018-08-31 DK DK18851555.5T patent/DK3677266T5/da active
- 2018-08-31 TW TW107130585A patent/TWI838345B/zh active
- 2018-08-31 HU HUE18851555A patent/HUE066587T2/hu unknown
- 2018-08-31 PT PT188515555T patent/PT3677266T/pt unknown
- 2018-08-31 CN CN202310869220.7A patent/CN117159551A/zh active Pending
- 2018-08-31 JO JOP/2020/0044A patent/JOP20200044A1/ar unknown
- 2018-08-31 ES ES18851555T patent/ES2972895T3/es active Active
- 2018-08-31 CA CA3224526A patent/CA3224526A1/en active Pending
- 2018-08-31 KR KR1020207008984A patent/KR102676530B1/ko active IP Right Grant
- 2018-08-31 WO PCT/JP2018/032314 patent/WO2019045036A1/ja unknown
- 2018-08-31 MX MX2020002296A patent/MX2020002296A/es unknown
- 2018-08-31 SG SG11202001861WA patent/SG11202001861WA/en unknown
- 2018-08-31 PL PL18851555.5T patent/PL3677266T3/pl unknown
- 2018-08-31 FI FIEP18851555.5T patent/FI3677266T3/fi active
- 2018-08-31 BR BR112020004000-2A patent/BR112020004000A2/pt unknown
- 2018-08-31 US US16/642,969 patent/US11701359B2/en active Active
- 2018-08-31 CA CA3074418A patent/CA3074418C/en active Active
- 2018-08-31 CN CN201880064210.3A patent/CN111465397B/zh active Active
- 2018-08-31 EP EP18851555.5A patent/EP3677266B1/en active Active
- 2018-08-31 AU AU2018325819A patent/AU2018325819B2/en active Active
- 2018-08-31 IL IL272929A patent/IL272929B2/en unknown
- 2018-08-31 JP JP2019539655A patent/JP7065103B2/ja active Active
-
2020
- 2020-03-02 PH PH12020500419A patent/PH12020500419A1/en unknown
- 2020-03-06 ZA ZA2020/01445A patent/ZA202001445B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001445B (en) | Exon 18 and/or exon 21 mutant egfr selective inhibitor | |
| MX2021013662A (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. | |
| MX2021013661A (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos. | |
| MX2019013634A (es) | Composiciones y metodos para tratar cancer con mutaciones de braf atipicas. | |
| JOP20190073A1 (ar) | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 | |
| MX2020012261A (es) | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. | |
| ZA202202097B (en) | Amino pyrimidine ssao inhibitors | |
| MX2017004234A (es) | Inhibidor del egfr y preparacion y aplicacion del mismo. | |
| EA201692472A1 (ru) | Соединения для лечения рака мозга | |
| NZ742480A (en) | Combination therapy for treating malignancies | |
| MX2018001737A (es) | Mecanismo de resistencia a inhibidores de bromodominio bet. | |
| MX2021015628A (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso. | |
| MX2019010149A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
| ZA202104679B (en) | L718 and/or l792 mutant treatment-resistant egfr inhibitor | |
| ZA201901322B (en) | Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| ZA202000354B (en) | Novel braf inhibitors and use thereof for treatment of cutaneous reactions | |
| MX2022005358A (es) | Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso. | |
| PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
| MX2022010939A (es) | Novedosos derivados sustituidos como inhibidores de la d-aminoacido oxidasa (daao). | |
| MX2022006278A (es) | Proteinas de salmon uk 114 para uso en el tratamiento, diagnostico y prevencion de tumores malignos. | |
| IL286649A (en) | The history of quinoline and its use in cancer treatment | |
| MX2020009829A (es) | Composiciones farmaceuticas de saposina c y metodos para tratar el cancer. | |
| MX2022002607A (es) | Metodos de tratamiento. |